CARTHERICS GRANTED EUROPEAN PATENT FOR MULTIPLE DEVELOPMENT CANDIDATES

2024-05-23

免疫疗法

Melbourne, Australia, 23 May 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family represented by the international patent filing WO2017088012. The European Patent No. 3708587 B1, titled 'Genetically Modified Cells and Uses Thereof,' secures a proprietary position for multiple development candidates in the Company’s pipeline. Specifically, this patent covers stem cells bearing the Cartherics’ chimeric antigen receptor (CAR) targeting the tumour-associated glycoprotein-72 (TAG-72). It also provides protection for allogeneic (off-the-shelf) immune cell products derived from the stem cells carrying the TAG-72 CAR. TAG-72 is highly expressed on a range of adenocarcinomas, including ovarian and gastric cancers. Issuance of the patent is an important milestone in the development of new treatments for these cancers and adds to Cartherics’ substantial intellectual property portfolio. Cartherics’ initial target indication is relapsed or refractory ovarian cancer, where greater than 90 percent of tumours are TAG-72 positive. Targeting these tumours with novel cellular immunotherapies will help address the unmet need for new treatment options for these patients. Cartherics’ CEO, Prof. Alan Trounson AO, commented: “Cartherics has invested heavily to secure patent protection for different aspects of its technology platform. The issuance of this European patent adds to the web of patents underpinning development and commercialisation of the Company’s products, in particular its lead product, CTH-401.” ****** About Cartherics  Cartherics is a privately held biotechnology company based in Melbourne, Australia that is rearming the body’s immune system to fight cancer.  It is developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products.  The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system.  The iPSCs are genetically engineered at specific “safe harbour” genomic sites to provide enhanced function for the derived NK and other immune cells. The Company’s lead product, CTH-401, is a CAR-NK cell product. It carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression.  Media contact Christine Filippis  Teraze Communications Phone: +61 419 119 866  Email: christine@teraze.com.au

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构